Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 151: Eculizumab, an anti-C5 monoclonal antibody, is used in the treatment of which condition?

A. Non-Hodgkin's lymphoma (NHL)
B. Hodgkin's lymphoma
C. Multiple myeloma
D. Paroxysmal nocturnal hemoglobinuria (Correct Answer)

Explanation: **Explanation:** **Eculizumab** is a humanized monoclonal antibody that targets the **C5 complement protein**. By binding to C5, it inhibits its cleavage into C5a and C5b, thereby preventing the formation of the **Membrane Attack Complex (MAC/C5b-9)**. 1. **Why Option D is Correct:** **Paroxysmal Nocturnal Hemoglobinuria (PNH)** is caused by an acquired mutation in the *PIGA* gene, leading to a deficiency of GPI-anchored proteins like **CD55 and CD59** on red blood cells. These proteins normally protect cells from complement-mediated lysis. In their absence, the alternative complement pathway causes chronic intravascular hemolysis. Eculizumab prevents this hemolysis by blocking the terminal complement cascade. 2. **Why Other Options are Incorrect:** * **Options A & B (Lymphomas):** Non-Hodgkin’s Lymphoma is typically treated with **Rituximab** (anti-CD20), while Hodgkin’s Lymphoma may involve **Brentuximab vedotin** (anti-CD30). Eculizumab has no role in treating lymphoid malignancies. * **Option C (Multiple Myeloma):** This is treated with proteasome inhibitors (Bortezomib), immunomodulators (Lenalidomide), or monoclonal antibodies like **Daratumumab** (anti-CD38). **High-Yield Clinical Pearls for NEET-PG:** * **Black Box Warning:** Eculizumab significantly increases the risk of **Meningococcal infections** (*Neisseria meningitidis*). Patients **must** be vaccinated with meningococcal vaccines at least 2 weeks prior to starting therapy. * **Other Indications:** It is also FDA-approved for **Atypical Hemolytic Uremic Syndrome (aHUS)**, Myasthenia Gravis (AChR-antibody positive), and Neuromyelitis Optica Spectrum Disorder (NMOSD). * **Ravulizumab** is a newer, longer-acting C5 inhibitor used for similar indications.

Question 152: Eculizumab is used in the treatment of which condition?

A. Acne vulgaris
B. Asthma
C. Paroxysmal nocturnal hemoglobinuria (Correct Answer)
D. Autoimmune hemolytic anemia

Explanation: ### Explanation **Correct Answer: C. Paroxysmal nocturnal hemoglobinuria (PNH) [1]** **Mechanism of Action:** Eculizumab is a **humanized monoclonal antibody** that binds to the **C5 complement protein** [1]. By inhibiting the cleavage of C5 into C5a and C5b, it prevents the formation of the **Membrane Attack Complex (MAC)**. In PNH, red blood cells lack protective proteins (CD55 and CD59) due to a PIGA gene mutation, making them vulnerable to complement-mediated lysis. Eculizumab halts this intravascular hemolysis, reducing the need for transfusions and the risk of thrombosis. **Analysis of Incorrect Options:** * **A. Acne vulgaris:** Treated with retinoids (Isotretinoin), antibiotics (Doxycycline), or benzoyl peroxide. Monoclonal antibodies are not used here. * **B. Asthma:** Biological therapies for severe asthma include Omalizumab (anti-IgE), Mepolizumab (anti-IL-5), or Dupilumab (anti-IL-4/13), but not complement inhibitors. * **D. Autoimmune hemolytic anemia (AIHA):** While it involves hemolysis, the primary treatment involves corticosteroids, Rituximab (anti-CD20), or immunosuppressants. Eculizumab is specifically indicated for complement-mediated disorders like PNH and Atypical Hemolytic Uremic Syndrome (aHUS). **High-Yield Clinical Pearls for NEET-PG:** 1. **Black Box Warning:** Eculizumab significantly increases the risk of **Meningococcal infections** (Neisseria meningitidis) because the MAC is essential for killing encapsulated bacteria. 2. **Mandatory Pre-requisite:** Patients must receive the **Meningococcal vaccine** at least 2 weeks before starting therapy. 3. **Other Indications:** Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD). 4. **Ravulizumab:** A long-acting derivative of Eculizumab with a longer half-life, allowing for less frequent dosing.

Question 153: What is the recommended level of anticoagulation for most patients, as measured by INR?

A. 1.0-2.0
B. 2.5-3.5
C. 2.0-3.0 (Correct Answer)
D. 3.0-4.5

Explanation: **Explanation:** The **International Normalized Ratio (INR)** is a standardized way of reporting the Prothrombin Time (PT), primarily used to monitor the intensity of oral anticoagulant therapy with Vitamin K Antagonists (e.g., **Warfarin**). **1. Why 2.0–3.0 is the Correct Answer:** For most clinical indications—including the treatment and prevention of **Venous Thromboembolism (VTE)**, **Pulmonary Embolism**, and stroke prevention in **Atrial Fibrillation**—a target INR range of **2.0–3.0** is recommended. This range represents the "therapeutic window" where the risk of thromboembolic events is significantly reduced without excessively increasing the risk of serious bleeding. **2. Analysis of Incorrect Options:** * **Option A (1.0–2.0):** This is sub-therapeutic. An INR of 1.0 is normal for a healthy person not on anticoagulants. Values below 2.0 provide inadequate protection against clot formation. * **Option B (2.5–3.5):** This higher intensity range is reserved for specific high-risk scenarios, most notably patients with **mechanical prosthetic heart valves** (especially in the mitral position). * **Option D (3.0–4.5):** This range is generally avoided as it significantly increases the risk of intracranial and gastrointestinal hemorrhage without providing additional clinical benefit. **NEET-PG High-Yield Pearls:** * **Mechanism:** Warfarin inhibits **VKORC1**, preventing the γ-carboxylation of Factors **II, VII, IX, and X** and Proteins C and S. * **Monitoring:** Warfarin is monitored by **PT/INR** (Extrinsic pathway), while Heparin is monitored by **aPTT** (Intrinsic pathway). * **Bridge Therapy:** Because Warfarin initially causes a pro-thrombotic state (due to the short half-life of Protein C), it must be "bridged" with Heparin for the first 4–5 days. * **Antidote:** For immediate Warfarin reversal, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC); for non-emergency reversal, use **Vitamin K1**.

Question 154: Which of the following statements regarding ticlopidine is TRUE?

A. It blocks GpIIb/IIIa receptors on platelet membrane
B. It prevents ADP mediated platelet adenylyl cyclase inhibition (Correct Answer)
C. It inhibits thromboxane A2 synthesis in platelets
D. It does not prolong bleeding time

Explanation: ### Explanation **Mechanism of Action (The Correct Answer)** Ticlopidine is a first-generation **P2Y12 receptor antagonist** (Thienopyridine class). Under normal physiological conditions, ADP binds to the P2Y12 receptor, which is coupled to **Gi proteins**. This coupling leads to the **inhibition of adenylyl cyclase**, resulting in decreased intracellular cAMP levels, which facilitates platelet aggregation. By irreversibly blocking the P2Y12 receptor, ticlopidine **prevents this ADP-mediated inhibition of adenylyl cyclase**, thereby maintaining higher cAMP levels and inhibiting platelet activation. **Analysis of Incorrect Options** * **Option A:** GpIIb/IIIa receptors are the "final common pathway" for platelet aggregation. Drugs that block these include **Abciximab, Eptifibatide, and Tirofiban**, not ticlopidine. * **Option C:** Inhibition of Thromboxane A2 (TXA2) synthesis is the mechanism of **Aspirin** (via irreversible COX-1 inhibition). Ticlopidine does not affect the arachidonic acid pathway. * **Option D:** Since ticlopidine inhibits platelet aggregation, it **significantly prolongs bleeding time**. This is a characteristic pharmacodynamic effect of all potent antiplatelet agents. **NEET-PG High-Yield Pearls** * **Class:** Ticlopidine, Clopidogrel, and Prasugrel are **Thienopyridines** (Irreversible P2Y12 blockers). Ticagrelor is a **non-thienopyridine** (Reversible blocker). * **Adverse Effects:** Ticlopidine is rarely used now due to severe hematological toxicities, specifically **Neutropenia/Agranulocytosis** and **Thrombotic Thrombocytopenic Purpura (TTP)**. * **Monitoring:** If a patient is on ticlopidine, a CBC (Complete Blood Count) must be monitored frequently during the first 3 months of therapy.

Question 155: A patient is started on oral warfarin therapy. Which of the following coagulation factors shows the most rapid decline in blood levels after initiation of warfarin therapy?

A. Factor VII
B. Protein C (Correct Answer)
C. Factor X
D. Prothrombin (Factor II)

Explanation: **Explanation:** Warfarin acts as a Vitamin K antagonist, inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**. This prevents the γ-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, X) and endogenous anticoagulant proteins (Protein C and Protein S). The rate at which these factors decline in the blood depends entirely on their individual **half-lives**. * **Protein C** has the shortest half-life (approx. **6–8 hours**) among all the factors affected by warfarin. Because it disappears first, there is a transient period where the patient is actually in a "pro-thrombotic" state (hypercoagulable) because the natural anticoagulant (Protein C) is gone while the pro-coagulant factors (especially II and X) are still circulating. **Analysis of Incorrect Options:** * **Factor VII:** While Factor VII has the shortest half-life among the *clotting* factors (approx. 4–6 hours), **Protein C** is often cited as having a similarly rapid or slightly more clinically significant initial decline in the context of the "warfarin skin necrosis" phenomenon. In most competitive exams, if both are listed, Protein C is the preferred answer for the "most rapid decline." * **Factor X:** Has a moderate half-life of approximately 36–48 hours. * **Prothrombin (Factor II):** Has the longest half-life (approx. 60–72 hours) and is the last to decline. **Clinical Pearls for NEET-PG:** 1. **Warfarin-Induced Skin Necrosis:** Occurs due to the rapid depletion of Protein C, leading to microvascular thrombosis before the full anticoagulant effect is achieved. 2. **Heparin Bridge:** To prevent the above, heparin is always co-administered with warfarin ("bridging") until the INR reaches the therapeutic range. 3. **Monitoring:** Warfarin is monitored using **PT/INR** (Extrinsic pathway), primarily reflecting the decline in Factor VII initially.

Question 156: Which of the following is NOT an adverse effect of heparin?

A. Bleeding
B. Thrombocytopenia
C. Hypokalemia (Correct Answer)
D. Osteoporosis

Explanation: The correct answer is **C. Hypokalemia**. Heparin actually causes **Hyperkalemia**, not hypokalemia. **1. Why Hypokalemia is the correct answer (The Mechanism):** Heparin inhibits the synthesis of **aldosterone** in the adrenal cortex by reducing the number and affinity of angiotensin II receptors in the zona glomerulosa. Since aldosterone is responsible for excreting potassium and retaining sodium, its suppression leads to potassium retention, resulting in **hyperkalemia**. This effect can occur even with low-dose prophylactic heparin and is more pronounced in patients with diabetes or renal insufficiency. **2. Analysis of Incorrect Options:** * **A. Bleeding:** This is the most common adverse effect of heparin [2]. It is managed by stopping the drug or, in severe cases, administering the specific antidote, **Protamine sulfate** [1]. * **B. Thrombocytopenia:** Heparin-Induced Thrombocytopenia (HIT) is a serious immune-mediated reaction (Type II hypersensitivity) where IgG antibodies form against the Heparin-Platelet Factor 4 complex, leading to paradoxical thrombosis [3]. * **D. Osteoporosis:** Long-term heparin therapy (usually >3 months) can lead to bone loss and spontaneous fractures [2]. It occurs because heparin increases osteoclast activity and decreases osteoblast formation. **Clinical Pearls for NEET-PG:** * **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT** (target 1.5–2.5 times control). Low Molecular Weight Heparin (LMWH) usually does not require monitoring but can be checked using **Factor Xa assay** [2]. * **Antidote:** 1 mg of Protamine sulfate neutralizes 100 units of UFH [1]. It only partially neutralizes LMWH. * **Safe in Pregnancy:** Heparin does not cross the placenta and is the anticoagulant of choice during pregnancy (unlike Warfarin, which is teratogenic) [2].

Question 157: Which of the following is an indication for parenteral iron therapy?

A. Patient compliance
B. Intolerance to oral iron (Correct Answer)
C. When an immediate rise in hemoglobin is required, such as in a patient in labor
D. To decrease the duration of oral medication

Explanation: **Explanation:** Iron deficiency anemia is primarily managed with oral iron. However, **parenteral iron therapy** is reserved for specific clinical scenarios where oral administration is either impossible, ineffective, or unsafe. **Why Option B is Correct:** **Intolerance to oral iron** is the most common indication for parenteral therapy. Many patients experience significant gastrointestinal side effects (nausea, abdominal cramps, constipation, or metallic taste) that prevent them from completing the course. Other indications include malabsorption syndromes (e.g., Celiac disease, H. pylori gastritis), inflammatory bowel disease (where oral iron can exacerbate inflammation), and chronic kidney disease (CKD) patients on erythropoietin. **Analysis of Incorrect Options:** * **Option A & D:** While parenteral iron bypasses compliance issues and reduces the duration of treatment, these are not standard medical indications. Oral iron remains the first-line choice due to its safety profile and low cost. * **Option C:** This is a common misconception. Parenteral iron **does not** raise hemoglobin levels faster than oral iron; it only replenishes iron stores more rapidly. If an immediate rise in hemoglobin is required (e.g., a patient in labor or severe acute hemorrhage), **blood transfusion** is the treatment of choice. **High-Yield NEET-PG Pearls:** * **Rate of Response:** The rate of hemoglobin rise is the same for both oral and parenteral iron (approx. 0.7–1 g/dL per week). * **Dose Calculation:** The total dose of parenteral iron is calculated using the **Ganzoni Formula**: * *Total Iron Deficit (mg) = Body weight (kg) × (Target Hb - Actual Hb) × 2.4 + Iron stores (500 mg).* * **Safety:** Iron Dextran carries a risk of anaphylaxis; a **test dose** is mandatory. Newer preparations like Iron Sucrose and Ferric Carboxymaltose have a lower risk of hypersensitivity.

Question 158: Erythropoietin is absolutely necessary for the treatment of:

A. Liver failure
B. Heart failure
C. Lung failure
D. End-stage renal failure (Correct Answer)

Explanation: ### Explanation **Correct Option: D. End-stage renal failure** The primary physiological source of **Erythropoietin (EPO)** is the **peritubular interstitial cells of the renal cortex**. EPO is a glycoprotein hormone that stimulates the proliferation and differentiation of red blood cell precursors (erythroid progenitors) in the bone marrow. In **End-stage renal failure (ESRD)**, the kidneys are unable to produce sufficient EPO, leading to a predictable and severe normocytic, normochromic anemia. Recombinant human erythropoietin (Epoetin alfa) or its analogues (Darbepoetin) are considered the **gold standard and absolute treatment** for managing anemia of chronic kidney disease, significantly reducing the need for blood transfusions. **Why other options are incorrect:** * **A. Liver failure:** While the liver produces a small amount of EPO (approx. 10-15%), its failure primarily leads to coagulopathy and macrocytic anemia (due to folate deficiency or alcohol), not a primary EPO deficiency. * **B & C. Heart and Lung failure:** These conditions often lead to **hypoxia**, which actually triggers a physiological *increase* in EPO production by the kidneys to compensate for low oxygen levels (secondary polycythemia). EPO is not a treatment for the underlying failure of these organs. --- ### NEET-PG High-Yield Pearls * **Mechanism:** EPO acts via the **JAK-STAT signaling pathway** (Janus Kinase 2). * **Target Cells:** It primarily acts on **CFU-E** (Colony Forming Unit-Erythroid) cells. * **Side Effects:** The most important side effect of EPO therapy is **Hypertension** and an increased risk of **thromboembolic events** (due to increased blood viscosity). * **Iron Stores:** Always ensure adequate iron stores (ferritin) before starting EPO, as rapid erythropoiesis can lead to functional iron deficiency. * **Other Indications:** Anemia due to Zidovudine (HIV treatment), chemotherapy-induced anemia, and preoperative autologous blood donation.

Question 159: Hypercoagulability and dermal vascular necrosis are early appearing adverse effects of:

A. Clopidogrel
B. Heparin
C. Warfarin (Correct Answer)
D. Vitamin K

Explanation: ### Explanation **Correct Option: C (Warfarin)** Warfarin acts by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**, which prevents the gamma-carboxylation of Vitamin K-dependent clotting factors (II, VII, IX, and X) and endogenous anticoagulants (**Protein C and Protein S**). The early hypercoagulability and dermal necrosis occur due to the difference in the **half-lives** of these factors: * **Protein C and S** have very short half-lives (~6–8 hours). * **Clotting factors** (especially Factor II and X) have much longer half-lives (up to 60 hours). When Warfarin is started, Protein C and S levels drop rapidly while procoagulant factors remain active. This creates a transient **prothrombotic state**, leading to microvascular thrombosis in the skin and subcutaneous tissue, clinically manifesting as **Warfarin-induced Skin Necrosis**. To prevent this, Warfarin is always "bridged" with a fast-acting anticoagulant like Heparin. **Why other options are incorrect:** * **A. Clopidogrel:** An ADP-receptor (P2Y12) antagonist that inhibits platelet aggregation. Its main side effects are bleeding and, rarely, TTP (Thrombotic Thrombocytopenic Purpura). * **B. Heparin:** An indirect thrombin inhibitor. While it can cause **Heparin-Induced Thrombocytopenia (HIT)**, which is also a prothrombotic state, it does not typically cause the classic "dermal vascular necrosis" associated with Protein C depletion. * **D. Vitamin K:** This is the antidote for Warfarin overdose and promotes the synthesis of clotting factors; it does not cause necrosis. **High-Yield Clinical Pearls for NEET-PG:** * **Bridging Therapy:** Always start Heparin with Warfarin for the first 4–5 days to cover the "prothrombotic window." * **Treatment of Necrosis:** If skin necrosis occurs, stop Warfarin immediately and administer **Vitamin K** and **Fresh Frozen Plasma (FFP)** or Protein C concentrate. * **Teratogenicity:** Warfarin is contraindicated in pregnancy (causes **Fetal Warfarin Syndrome** - chondrodysplasia punctata); Heparin is the drug of choice.

Question 160: Iron dextran is indicated for which condition?

A. Macrocytic anemia (Correct Answer)
B. Severe blood loss
C. Iron deficiency anemia
D. Hookworm anemia

Explanation: **Explanation:** **Correct Option: A (Macrocytic anemia)** While Iron Dextran is primarily an iron supplement, this question tests a specific clinical scenario often encountered in NEET-PG: **Dimorphic Anemia**. In patients with macrocytic anemia (due to Vitamin B12 or Folic acid deficiency) [1, 3], the initiation of treatment leads to a rapid surge in erythropoiesis. This sudden demand for hemoglobin synthesis can deplete existing iron stores, leading to a secondary iron deficiency [3]. In such cases, parenteral iron like **Iron Dextran** is indicated to support the rapid red blood cell production triggered by B12/Folate therapy. **Incorrect Options:** * **B. Severe blood loss:** The immediate treatment for severe, acute blood loss is whole blood or packed red blood cell (PRBC) transfusion to restore volume and oxygen-carrying capacity, not iron supplementation. * **C. Iron deficiency anemia:** While Iron Dextran *is* used for iron deficiency, **Oral Iron** (e.g., Ferrous sulfate) is the first-line treatment. Parenteral iron is reserved only for patients with oral intolerance, malabsorption, or non-compliance [2]. * **D. Hookworm anemia:** The primary management involves anthelmintic therapy (Albendazole) to stop the loss, followed by oral iron to replenish stores. **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Iron Dextran can be given IM or IV. If given IM, use the **Z-track technique** to prevent skin staining. * **Adverse Effect:** It carries a high risk of **Type I Anaphylactic reactions**. A **test dose** is mandatory before the full dose. * **Calculation:** The total dose required is calculated using the **Haldane’s formula** (or Ganzoni equation). * **Modern Alternatives:** Iron Sucrose and Ferric Carboxymaltose are now preferred over Iron Dextran due to a lower risk of anaphylaxis [1].

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free